16+
Major trials tracked
Two antibody-drug conjugates in solid tumours
Sacituzumab govitecan vs trastuzumab deruxtecan: trial pipelines compared
A side-by-side view of the sacituzumab govitecan and trastuzumab deruxtecan clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for sacituzumab govitecan and 16+ for trastuzumab deruxtecan. Add up to three more drugs to widen the comparison.
sacituzumab govitecan (16) vs trastuzumab deruxtecan (16)30 active2016–2034
sacituzumab govitecantrastuzumab deruxtecan
'16
'18
'20
'22
'24
'26
'28
'30
'32
'34
sacituzumab govitecan
TROPiCS-03P2
SASCIAP3
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)P3
Scalp Cooling in MBCP2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)P2
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)P3
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)P2
Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyP2
ASCENT-GYN-01P3
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionP2
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCP2
OASISP2
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerP3
ADAPT-TN-IVP3
PROBEP2
trastuzumab deruxtecan
TAPURP2
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]P2
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]P3
DG-03P2
DPT01P2
Scalp Cooling in MBCP2
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsP3
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)P2
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsP2
DESTINY-BTC01P3
TRADE DXdP2
Perioperative Therapies in Locally Advanced Unresectable Gastric CancerP2
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerP3
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
ASPEN-09-03P2
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerP2
Upcoming readouts
24 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
sacituzumab govitecan (Trodelvy)Antibody-drug conjugates
6
Phase 3 trials
8
Actively recruiting
Dec 2026
Next phase 3 readout
trastuzumab deruxtecan (Enhertu)Antibody-drug conjugates
16+
Major trials tracked
4
Phase 3 trials
10
Actively recruiting
Jun 2028
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across sacituzumab govitecan and trastuzumab deruxtecan, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track sacituzumab govitecan and trastuzumab deruxtecan with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Individual pipelines and other comparisons
FAQ
- How do the sacituzumab govitecan and trastuzumab deruxtecan clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for sacituzumab govitecan and 16+ for trastuzumab deruxtecan. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.
